Chapter 44 in our book, The Courage to FACE COVID-19: Preventing Hospitalization and Death While Battling the Bio-Pharmaceutical Complex, details the clear benefit of nasal washes in the early stage of SARS-CoV-2 infection, when the virus is replicating in the nose. The logic of this simple, over-the-counter intervention is clear—namely, reduce the viral load BEFORE the infection migrates down into the lungs.
Through our research, we had the privilege of meeting Mr. Nathan Jones, CEO of XLEAR nasal spray, headquartered in American Fork, Utah. Decades ago, Nate’s father, Dr. Alonzo Jones, began an exhaustive study of the benefits of oral and nasal hygiene for preventing upper respiratory tract infections. Nate found his father’s research so compelling that he formulated a nasal spray based on Dr. Jones’s findings.
Shortly after SARS-CoV-2 arrived, Nate received word that doctors in the field were using XLEAR to reduce the severity of COVID-19. This prompted Nate to fund (at considerable expense) studies to determine if these observations in the field could be confirmed by laboratory testing and analysis, To his own surprise, multiple lab tests confirmed that a minor component of XLEAR nasal spray—i.e., its grapefruit seed extract preservative—destroys SARS-CoV-2.
As part of the U.S. government’s war on early treatment in order to promote mass vaccination, the Federal Trade Commission prohibited every company in the nasal hygiene space from making any claims about the benefit of their products in preventing SARS-CoV-2 infection, reducing its severity, or reducing its transmissibility. The Commission issued this prohibition in spite of numerous peer-reviewed studies in the medical literature showing that viricidal nasal rinses can indeed reduce the duration and severity of the illness.
Not only were companies like XLEAR prohibited from making any claims about the benefits of their products in fighting COVID-19 infection, they weren’t even allowed to share published studies about these benefits on their company websites.
While most of the companies in the nasal hygiene space bowed to FTC pressure, Nate refused to be intimidated. He decided to fight the FTC’s lawsuit in court. For an account of the FTC’s side of the story, see the Commission’s press release about its lawsuit.
Please take the time to listen to my interview with Mr. Jones—an enterprising and courageous man who refuses to be pushed around by the U.S. government. I would like to emphasize that he could have easily bowed to FTC pressure and avoided the enormous expense of fighting its lawsuit. Though XLEAR could enjoy an economic benefit if it prevails in court, Nate is fighting the lawsuit primarily as a matter or principle and his dedication to discovering and telling the truth.
The Clear Benefits of Nasal Hygiene